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Abstract. This paper considers conducting inference about the effect
of a treatment (or exposure) on an outcome of interest. In the ideal set-
ting where treatment is assigned randomly, under certain assumptions
the treatment effect is identifiable from the observable data and infer-
ence is straightforward. However, in other settings such as observational
studies or randomized trials with noncompliance, the treatment effect
is no longer identifiable without relying on untestable assumptions.
Nonetheless, the observable data often do provide some information
about the effect of treatment, that is, the parameter of interest is par-
tially identifiable. Two approaches are often employed in this setting:
(i) bounds are derived for the treatment effect under minimal assump-
tions, or (ii) additional untestable assumptions are invoked that render
the treatment effect identifiable and then sensitivity analysis is con-
ducted to assess how inference about the treatment effect changes as
the untestable assumptions are varied. Approaches (i) and (ii) are con-
sidered in various settings, including assessing principal strata effects,
direct and indirect effects and effects of time-varying exposures. Meth-
ods for drawing formal inference about partially identified parameters
are also discussed.
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1. INTRODUCTION
In many areas of science, interest often lies in as-
sessing the causal effect of a treatment (or exposure)
on some particular outcome of interest. For exam-
ple, researchers may be interested in estimating the
difference between the average outcomes when all
individuals are treated (exposed) versus when all in-
dividuals are not treated (unexposed). When treat-
ment is assigned randomly and there is perfect com-
pliance to treatment assignment, such treatment ef-
fects are identifiable and inference about the effect of
treatment proceeds in a straightforward fashion. On
the other hand, if the treatment assignment mech-
anism is not known to the analyst or compliance
is not perfect, then these treatment effects are not
identifiable from the observable data.
A statistical parameter is considered identifiable
if different values of the parameter give rise to differ-
ent probability distributions of the observable ran-
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dom variables. A parameter is partially identifiable
if more than one value of the parameter gives rise
to the same observed data law, but the set of such
values is smaller than the parameter space. Tradi-
tionally, statistical inference has been restricted to
the situation when parameters are identifiable. More
recent research has considered methods for conduct-
ing inference about partially identifiable parameters.
This research has been motivated to some extent
by methods to evaluate causal effects of treatment,
which are frequently partially identifiable. For in-
stance, causal estimands are typically only partially
identifiable in observational studies where the treat-
ment selection mechanism is not known to the ana-
lyst. Noncompliance in randomized trials may also
render treatment effects partially identifiable and a
large amount of research has been devoted to draw-
ing inference about treatment effects in the pres-
ence of noncompliance. Partial identifiability also
arises when drawing inference about treatment ef-
fects within principal strata or effects describing re-
lationships between an outcome and a treatment
that are mediated by some intermediate variable.
In order to conduct inference about treatment ef-
fects that are partially identifiable, two approaches
are often employed: (i) bounds are derived for the
treatment effect under minimal assumptions, or (ii)
additional untestable assumptions are invoked un-
der which the treatment effect is identifiable and
then sensitivity analysis is conducted to assess how
inference about the treatment effect changes as the
untestable assumptions are varied. Below (i) and (ii)
are illustrated in five settings. In Section 2, we con-
sider treatment effect bounds and sensitivity anal-
ysis when the treatment assignment mechanism is
unknown. In Section 3, partial identifiability of prin-
cipal strata causal effects are discussed. In Section 4,
the setting of noncompliance is considered where
there is interest in assessing the effect of treatment if
there was perfect compliance. In Section 5, bounds
and sensitivity analysis for direct and indirect effects
in mediation analysis are presented, and in Section 6
longitudinal treatment effects are considered. Much
of the literature on bounds and sensitivity analy-
sis focuses on ignorance due to partial identifiability
and tends to ignore uncertainty due to sampling er-
ror. Section 7 presents some methods that appropri-
ately quantify this uncertainty when drawing infer-
ence about partially identifiable treatment effects.
Section 8 concludes with a discussion.
2. TREATMENT SELECTION
2.1 Minimal Assumptions Bounds
Suppose we have a random sample of individuals
where each potentially receives treatment or control.
Unless otherwise indicated, let Z indicate treatment
received where Z = 1 denotes treatment and Z = 0
denotes control. Denote the observed outcome of in-
terest by Y . In order to define a treatment effect
on the outcome Y , we first define potential out-
comes for an individual when receiving treatment,
denoted Y (1), and when receiving control, denoted
Y (0). Throughout this paper, we invoke the stable
unit treatment value assumption (SUTVA; Rubin
(1980)), that is, there is no interference between
units and there are no hidden (unrepresented) forms
of treatment such that each individual has two po-
tential outcomes {Y (0), Y (1)}. The no hidden forms
of treatment guarantees that the observed outcome
is equal to the potential outcome corresponding to
the observed treatment, namely that Y = Y (z) for
Z = z. Here, this will be referred to as causal consis-
tency; for further discussion of causal consistency see
Pearl (2010) and references therein. Once an indi-
vidual receives treatment Z, the potential outcome
Y (Z) is observed and the other potential outcome
(or counterfactual) Y (1− Z) becomes missing. As-
sume that n i.i.d. copies of (Z,Y ) are observed and
denoted by (Zi, Yi) for i= 1, . . . , n.
In this section, we consider treatment effect
bounds when the treatment assignment mechanism
is unknown. Here, Z can be thought of as treat-
ment selection by the individual or by nature, rather
than random treatment assignment as in an exper-
iment. Define the average treatment effect ATE to
be E[Y (1) − Y (0)] = E[Y (1)] − E[Y (0)] where E
denotes the expected value. The ATE can be de-
composed as
1∑
z=0
E[Y (1)|Z = z]Pr[Z = z]
(1)
−
1∑
z=0
E[Y (0)|Z = z]Pr[Z = z].
Note E[Y (z)|Z = z] = E[Y |Z = z] by causal consis-
tency. Thus, from the observed data E[Y (z)|Z = z]
and Pr[Z = z] are identifiable and can be consis-
tently estimated by their empirical counterparts. On
the other hand, the observed data provide no in-
formation about E[Y (z)|Z = 1 − z], such that (1)
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is only partially identifiable without additional as-
sumptions.
Bounds on E[Y (1)−Y (0)] can be obtained by en-
tertaining the smallest and largest possible values
for E[Y (z)|Z = 1 − z]. If Y (1) and Y (0) are not
bounded then bounds on E[Y (1) − Y (0)] will be
completely uninformative, ranging from −∞ to ∞.
Thus, informative bounds are only possible if Y (0)
and Y (1) are bounded. Because any bounded vari-
able can be rescaled to take values in the unit inter-
val, without loss of generality assume Y (z) ∈ [0,1]
for z = 0,1. Then 0 ≤ E[Y (z)|Z = 1 − z] ≤ 1 and
from (1) it follows that E[Y (1)− Y (0)] is bounded
below by setting E[Y (1)|Z = 0] = 0 and E[Y (0)|Z =
1] = 1, which yields the lower bound
E[Y (1)|Z = 1]Pr[Z = 1]
(2)
−E[Y (0)|Z = 0]Pr[Z = 0]−Pr[Z = 1].
Similarly, E[Y (1)− Y (0)] is bounded above by set-
ting E[Y (1)|Z = 0] = 1 and E[Y (0)|Z = 1] = 0,
which yields the upper bound
E[Y (1)|Z = 1]Pr[Z = 1]
(3)
−E[Y (0)|Z = 0]Pr[Z = 0] +Pr[Z = 0].
These bounds were derived independently by Robins
(1989) and Manski (1990). The lower and upper
bounds (2) and (3) are sharp in the sense that it
is not possible to derive narrower bounds without
additional assumptions. Note the interval formed by
(2) and (3) is contained in [−1,1] and is of width 1.
Thus, the bounds are informative in that the treat-
ment effect is now restricted to half of the other-
wise possible range [−1,1]. On the other hand, the
bounds will always contain the null value 0 corre-
sponding to no average treatment effect. That is,
without additional assumptions the sign of the treat-
ment effect cannot be determined from the observ-
able data.
2.2 Additional Assumptions
The bounds (2)–(3) are sometimes called the “no
assumptions” or “worst case” bounds because no as-
sumptions are made about the effect of treatment
in the population (Lee (2005); Morgan and Winship
(2007)). The only assumptions made in deriving (2)
and (3) are SUTVA and that the observed data con-
stitute a random sample. If additional assumptions
are invoked, the treatment effect bounds may be-
come tighter (i.e., narrower) or even collapse to a
point (i.e., the treatment effect may become identi-
fiable). Sometimes these additional assumptions will
have implications that are testable based on the ob-
served data. Should the observed data provide ev-
idence against an assumption under consideration,
then bounds should be computed without making
this assumption.
An example of an additional assumption is mean
independence, that is,
E[Y (z)|Z = 0] =E[Y (z)|Z = 1] for z = 0,1.(4)
Under (4) ATE is identifiable. Specifically the upper
and lower bounds for ATE both equal E[Y (1)|Z =
1] − E[Y (0)|Z = 0], which is identifiable from the
observable data and can be consistently estimated
by the “naive” estimator given by the difference in
sample means between the groups of individuals re-
ceiving treatment and control. Assumption (4) will
hold in experiments where treatment is randomly
assigned as in a randomized clinical trial. Moreover,
in randomized experiments the stronger assumption
Y (z)∐Z for z = 0,1,(5)
will hold, where ∐ denotes independence. Indepen-
dent treatment assignment (5) implies mean inde-
pendence (4).
In some settings it may be reasonable to consider
additional assumptions that are not as strong as
(4) or (5) but nonetheless lead to tighter bounds
than (2) and (3). For example, monotonicity type
assumptions might be considered, such as monotone
treatment selection (MTS)
E[Y (z)|Z = 1]≥E[Y (z)|Z = 0] for z = 0,1.(6)
MTS assumes individuals who select treatment will
on average have outcomes greater than or equal to
that of individuals who do not select treatment un-
der the counterfactual scenario all individuals se-
lected the same z. Manski and Pepper (2000) con-
sider MTS when examining the effect of returning to
school on wages later in life. For this example, MTS
implies individuals who choose to return to school
will have higher wages on average compared to in-
dividuals who choose to not return to school under
the counterfactual scenario no individuals return to
school. Alternatively, one might assume monotone
treatment response (MTR)
Pr[Y (1)≥ Y (0)] = 1
(Manski (1997)). MTR assumes that under treat-
ment each individual will have a response greater
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than or equal to that under control. For instance,
suppose Z = 1 if an individual elects to get the an-
nual influenza vaccine and Z = 0 otherwise, and let
Y (z) = 1 if an individual subsequently does not de-
velop flu-like symptoms when Z = z, and Y (z) = 0
otherwise. MTR asserts that each individual is more
or as likely to not develop flu-like symptoms if
they are vaccinated versus if they are unvaccinated.
Given to date there is no evidence that the annual
flu vaccine enhances the probability of acquiring in-
fluenza, MTR might be plausible for this example.
Assuming MTS or MTR can lead to narrower
bounds than (2) and (3) because they imply addi-
tional constraints on unobserved counterfactual ex-
pectations. For example, assumingMTS, E[Y (0)|Z =
1] is bounded below byE[Y (0)|Z = 0] and E[Y (1)|Z =
0] is bounded above by E[Y (1)|Z = 1], implying the
upper bound on E[Y (1)− Y (0)] is
E[Y (1)|Z = 1]−E[Y (0)|Z = 0],(7)
for which the naive estimator is consistent. Un-
der MTS, the lower bound remains (2). In contrast
to the no assumptions bounds, assuming MTS the
bounds may exclude 0, specifically when (7) is nega-
tive. MTR implies E[Y (1)]≥E[Y (0)] which in turn
implies that the ATE lower bound is 0. Under MTR,
the upper bound remains (3).
2.3 AZT Example
To illustrate the bounds above, consider a hypo-
thetical study of 2000 HIV patients (from Figure 2
of Robins (1989)) where 1400 individuals elected to
take the drug AZT and 600 elected not to take AZT
(this is a simplified version of the problem Robins
considers). The outcome of interest is death or sur-
vival at a given time point. Of the 2000 patients,
1000 died with exactly 500 from each group. Let
Z = 1 if the patient elected to take AZT and Z = 0
otherwise; let Y = 1 if the individual died and 0
otherwise. The naive estimator, that is, the differ-
ence in sample means between Z = 1 and Z = 0,
equals 500/1400 − 500/600 ≈ −0.48. The empirical
estimates of the no assumptions bounds (2) and (3)
equal −0.7 and 0.3. In this setting, the MTS as-
sumption (6) supposes that individuals who elected
to take AZT would have been more or as likely to die
as individuals who did not take AZT in the coun-
terfactual scenarios where everyone receives treat-
ment or everyone does not receive treatment. This
might be reasonable if it is thought that those who
took AZT were on average less healthy than those
who did not. Assuming MTS, the upper bound (7)
is estimated to be −0.48. Thus, in this example
the MTS bounds are substantially tighter than the
no assumption bounds. The estimated MTS bounds
lead to the conclusion (ignoring sampling variability,
a point which we return to later) that AZT reduces
the probability of death by at least 0.48 whereas
without the MTS assumption we cannot even con-
clude whether the effect of treatment is nonzero.
2.4 Sensitivity Analysis
Assumptions such as (4) or (5) which identify the
ATE, or assumptions such as MTS which sharpen
the bounds, cannot be tested empirically because
such assumptions pertain to the counterfactual dis-
tribution of Y (z) given Z = 1−z. Robins and others
(e.g., see Robins, Rotnitzky and Scharfstein (2000);
Scharfstein, Rotnitzky and Robins (1999)) have ar-
gued that a data analyst should conduct sensitivity
analysis to explore how inference varies as a function
of departures from any untestable assumptions.
For instance, a departure from assumption (5)
might be due to the existence of an unmeasured
variable U associated with both treatment selection
Z and the potential outcomes Y (z) for z = 0,1; a
variable such as U is often referred to as an unmea-
sured confounder. Under this scenario, one might
postulate that Y (z) ∐ Z|U for z = 0,1 rather than
(5). Sensitivity analysis proceeds by examining how
inference drawn about ATE varies as a function of
the magnitude of the association of U with Z, Y (0),
and Y (1). This idea has roots as early as Cornfield
et al. (1959), who demonstrated the plausibility of a
causal effect of cigarette smoking (Z) on lung cancer
(Y ) by arguing that the absence of such a relation-
ship was only possible if there existed an unmea-
sured factor U associated with cigarette use that
was at least as strongly associated with lung cancer
as cigarette use. This idea was further developed by
Schlesselman (1978), Rosenbaum and Rubin (1983),
Lin, Psaty and Kronmal (1998), Herna´n and Robins
(1999) and VanderWeele and Arah (2011) among
others.
To illustrate this approach, suppose in the AZT
example above that the analyst first assumes (5)
holds, and thus estimates the effect of AZT to be
−0.48. To proceed with sensitivity analysis, the an-
alyst posits the existence of an unmeasured binary
variable U and assumes that Y (z)∐Z|U for z = 0,1.
Similar to VanderWeele and Arah (2011), let
c(z) = {E[Y (z)|U = 1]−E[Y (z)|U = 0]}
· {Pr[U = 1|Z = z]−Pr[U = 1]}.
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Then under the assumption that Y (z) ∐ Z|U for
z = 0,1, the naive estimator converges in proba-
bility to E[Y (1)]− E[Y (0)] + c(1)− c(0). Thus the
naive estimator is asymptotically unbiased if and
only if c(1) = c(0). For an alternative decomposition
of the asymptotic bias of the naive estimator, see
Morgan and Winship (2007, Section 2.6.3).
Sensitivity analysis proceeds by making varying
assumptions about the unidentifiable associations of
U with Y (0), Y (1) and Z. Under the most extreme
of these assumptions, the bounds (2) and (3) are
recovered. In particular, the upper bound in (3) is
achieved when Pr[U = 1|Z = 1] = 0, Pr[U = 1|Z =
0] = 1, E[Y (1)|U = 1] = 1 and E[Y (0)|U = 0] = 0,
meaning that the confounder U is perfectly nega-
tively correlated with treatment Z and that if the
confounder is present (U = 1), then a treated indi-
vidual will die, whereas if the confounder is absent
(U = 0), then an untreated individual will survive.
The lower bound (2) is achieved under the opposite
conditions.
In practice the extreme associations of U with
Y (0), Y (1), and Z leading to the bounds might
be considered unrealistic. Instead the analyst might
consider associations only in a range deemed plau-
sible by subject matter experts. In order to ar-
rive at an accurate range, care should be taken in
communicating the meaning of these associations
and eliciting this range should be done in a man-
ner that avoids data driven choices. Alternatively,
the degree of associations required to change the
sign of the effect of interest might be determined.
For instance, suppose the analyst further assumes
that E[Y (z)|U = 1] − E[Y (z)|U = 0] does not de-
pend on z. This assumption will hold if the ef-
fect of Z on Y is the same if U = 0 or U = 1.
Letting γ0 = E[Y (z)|U = 1] − E[Y (z)|U = 0] and
γ1 =Pr[U = 1|Z = 1]−Pr[U = 1|Z = 0], the asymp-
totic bias of the naive estimator is then given by γ0γ1
and a bias adjusted estimator is found by subtract-
ing γ0γ1 from the naive estimator. Sensitivity analy-
sis may proceed by determining the values of γ0 and
γ1 for which the bias adjusted estimator of the ATE
will have the opposite sign of the naive estimator.
For the AZT example, the bias adjusted estimator
will have the opposite sign of the naive estimator if
γ0γ1 <−0.48. This indicates that the product of (i)
the difference in the mean potential outcomes be-
tween levels of the confounder for both treatment
and control, and (ii) the difference in the prevalence
of the unmeasured confounder between the treat-
ment and control groups must be less than −0.48.
Such magnitudes might be considered unlikely in the
opinion of subject matter experts, in which case the
sensitivity analysis would support the existence of
a beneficial effect of AZT on survival among HIV+
men (ignoring sampling variability). Note the ob-
served data distribution places some restrictions on
the possible values of (γ0, γ1), that is, (γ0, γ1) is
partially identifiable. For instance, if γ1 = 1 then
Pr[U = 1|Z = 1] = 1 and Pr[U = 1|Z = 0] = 0 which
implies E[Y (z)|U = u] = E[Y (z)|Z = u] and, there-
fore, max{E[Y (1)|Z = 1] − 1,−E[Y (0)|Z = 0]} ≤
γ0 ≤ min{E[Y (1)|Z = 1],1 − E[Y (0)|Z = 0]}. Such
considerations should be taken into account when
determining the range of values of (γ0, γ1) in sensi-
tivity analysis.
Because the data provide no evidence about
U , VanderWeele (2008) and VanderWeele and Arah
(2011) recommend choosing U and any simplifying
assumptions based on what is considered plausible
by relevant subject-matter experts. Such sensitivity
analyses are most applicable when the existence of
unmeasured confounders is known, but these factors
could not be measured for logistical or other reasons.
General bias formulas to be used for sensitivity anal-
yses of unmeasured confounding for categorical or
continuous outcomes, confounders and treatments
can be found in VanderWeele and Arah (2011).
In other settings, there might not be any known
unmeasured confounders, or it may be thought
that there are numerous unmeasured confounders,
in which cases the sensitivity analysis strategy de-
scribed above would not be applicable or feasi-
ble. One general alternative approach entails mak-
ing additional untestable assumptions regarding the
unobserved potential outcome distributions. Typi-
cally, these assumptions (or models) are indexed by
one or more sensitivity analysis parameters condi-
tional upon which the causal estimand of interest is
identifiable (e.g., Scharfstein, Rotnitzky and Robins
(1999); Brumback et al. (2004)). Sensitivity analysis
then proceeds by examining how inference changes
as assumed values of the parameters are varied over
plausible ranges. Examples of such sensitivity anal-
yses are given below in Sections 3.4 and 6.3.
2.5 Covariate Adjustment
Typically in observational studies baseline (pre-
treatment) covariates X will be collected in addi-
tion to Z and Y . Incorporating information from ob-
served covariates can help sharpen inferences about
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partially identified treatment effects. For example,
incorporating covariates will generally lead to nar-
rower bounds (Scharfstein, Rotnitzky and Robins
(1999)). This follows because any treatment effect
compatible with the distribution of observed vari-
ables (X,Y,Z) must also be compatible with the
distribution of (Y,Z), that is, the observable vari-
ables if we do not observe or choose to ignore X
(Lee (2009)). Covariate adjusted bounds are dis-
cussed further in Section 3.3 below.
Additionally, incorporating covariates may lend
plausibility to some of the bounding assumptions
discussed in Section 2.2. For example, in the absence
of randomized treatment assignment (4) or (5) may
be dubious. Instead of (4), it might be more plausi-
ble to assume
E[Y (z)|Z = 0,X = x]
(8)
=E[Y (z)|Z = 1,X = x] for z = 0,1.
Similarly, assumption (5) might be replaced by
Y (z)∐Z|X for z = 0,1,(9)
that is, each potential outcome is independent of
treatment selection conditional on some set of co-
variates. Assumption (9) is commonly referred to as
no unmeasured confounders. Assumptions such as
(8) or weaker inequalities similar to (6) such as
E[Y (z)|Z = 1,X = x]
≥E[Y (z)|Z = 0,X = x] for z = 0,1,
may be deemed plausible for certain levels of X , but
not for others. Availability of covariates also allows
for the consideration of new types of assumptions
(e.g., see Chiburis (2010)).
To conduct covariate adjusted sensitivity analysis,
departures from identifying assumptions such as (9)
can be explored. Similar to the previous section, a
departure from (9) might entail positing the exis-
tence of an unmeasured variable U associated with
both treatment selection Z and the potential out-
comes Y (z) for z = 0,1. Under this scenario, one
might postulate that Y (z) ∐ Z|{X,U} for z = 0,1
rather than (9) and sensitivity analysis proceeds by
examining how inference varies as a function of the
magnitude of the association of U with Z, Y (0), and
Y (1) given X . Similar to covariate adjusted bounds,
smaller associations or tighter regions of the values
of the sensitivity parameters may be deemed plau-
sible within certain levels of X , potentially yield-
ing sharper inferences from the sensitivity analyses.
However, as cautioned by Robins (2002), care should
be taken in clearly communicating the meaning of
such sensitivity parameters and their relationship to
covariates when eliciting plausible ranges from sub-
ject matter experts. In some scenarios, plausible re-
gions for sensitivity parameters may in fact be wider
when conditioning on X than when not conditioning
on X .
3. PRINCIPAL STRATIFICATION
3.1 Background
Even if treatment is randomly assigned (e.g., as
in a clinical trial), the causal estimand of interest
may still be only partially identifiable. For exam-
ple, in many studies it is often of interest to draw
inference about treatment effects on outcomes that
only exist or are meaningful after the occurrence of
some observable intermediate variable. For instance,
in studies where some individuals die, investigators
might be interested in treatment effects only among
individuals alive at the end of the study. Unfortu-
nately, estimands defined by contrasting mean out-
comes under treatment and control that simply con-
dition on this observable intermediate variable do
not measure a causal effect of treatment without
additional assumptions. One approach that may be
employed in this scenario entails principal stratifica-
tion (Frangakis and Rubin (2002)). Principal strati-
fication uses the potential outcomes of the interme-
diate post-randomization variable to define strata
of individuals. Because these “principal strata” are
not affected by treatment assignment, treatment ef-
fect estimands defined within principal strata have
a causal interpretation and do not suffer from the
complications of standard post-randomization ad-
justed estimands. The simple framework of principal
stratification has a wide range of applications. For
a recent discussion of the utility (and lack thereof)
of principal stratification, see Pearl (2011) and cor-
responding reader reactions.
As a motivating example for this section, we con-
sider evaluating vaccine effects on post-infection
outcomes. In vaccine studies, uninfected subjects
are enrolled and followed for infection endpoints,
and infected subjects are subsequently followed for
post-infection outcomes such as disease severity or
death due to infection with the pathogen targeted
by the vaccine; often interest is in assessing the
effect of vaccination on these post-infection end-
points (Hudgens and Halloran (2006)). For exam-
ple, Pre´ziosi and Halloran (2003) present data from
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a pertussis vaccine field study in Niakhar, Senegal.
In this study, 3845 vaccinated children and 1020 un-
vaccinated children were followed for one year for
pertussis. In the vaccine group, 548 children con-
tracted pertussis, of whom 176 had severe infec-
tions; in the unvaccinated group 206 children con-
tracted pertussis, of whom 129 had severe infections.
In this setting, investigators are interested in assess-
ing whether or not the vaccine had an effect on the
severity of infection.
When assessing such post-infection effects, a data
analyst might consider contrasts between study
arms including all individuals under study, or, alter-
natively, only those who become infected. Though
including all individuals in the study has the advan-
tage of providing valid inference about the overall ef-
fect of vaccination (assuming independent treatment
assignment), such an approach does not distinguish
vaccine effects on susceptibility to infection from ef-
fects on the post-infection endpoint of interest. An
analysis that conditions on infection attempts to
distinguish these effects and may be more sensitive
in detecting post-infection vaccine effects. However,
because the set of individuals who would become
infected under control are not likely to be the same
as those who would become infected if given the
vaccine, conditioning on infection might result in se-
lection bias. For example, those who would become
infected under vaccine may tend to have weaker im-
mune systems than those who would become in-
fected under control, and thus may be more suscep-
tible to severe infection. Because of this potential
selection bias, comparisons between infected vacci-
nees and infected controls do not necessarily have
causal interpretations.
3.2 Principal Effects
In this section, treatment is vaccination, with
Z = 1 corresponding to vaccination and Z = 0 cor-
responding to not being vaccinated. Assume that
assignment to vaccine is equivalent to receipt of vac-
cine, that is, there is no noncompliance. Denote the
potential infection outcome by S(z), where S(z) = 0
if uninfected and S(z) = 1 if infected. Here, the focus
is on evaluating the causal effect of vaccine on Y , a
post-infection outcome. For simplicity, we consider
the case where Y is binary, indicating the presence
of severe disease. If S(z) = 1, define the potential
post-infection outcome Y (z) = 1 if the individual
would have the worse (or more severe) post-infection
outcome of interest given z, and Y (z) = 0 other-
wise. If an individual’s potential infection outcome
for treatment z is uninfected [i.e., S(z) = 0], then
we adopt the convention that Y (z) is undefined. In
other words, it does not make sense to define the
severity of an infection in an individual who is not
infected. This convention is similar to that employed
in other settings. For instance, in the analysis of
quality of life studies it might be assumed that qual-
ity of life metrics are not well defined in those who
are not alive (Rubin (2000)).
Define a basic principal stratification P0 accord-
ing to the joint potential infection outcomes SP0 =
(S(0), S(1)). The four basic principal strata or re-
sponse types are defined by the joint potential infec-
tion outcomes, (S(0), S(1)), and are composed of im-
mune (not infected under both vaccine and placebo),
harmed (infected under vaccine but not placebo),
protected (infected under placebo but not vaccine),
and doomed individuals (infected under both vac-
cine and placebo). Note the only stratum where both
potential post-infection endpoints are well defined is
in the doomed basic principal stratum, SP0 = (1,1).
Thus, defining a post-infection causal vaccine effect
is only possible in the doomed principal stratum
SP0 = (1,1). Such a causal estimand will describe
the effect of vaccination on disease severity in in-
dividuals who would become infected whether vac-
cinated or not. For instance, the vaccine effect on
disease severity may be defined by
E[Y (1)|SP0 = (1,1)]
(10)
−E[Y (0)|SP0 = (1,1)].
Frangakis and Rubin call treatment effect estimands
such as (10) “principal effects.”
3.3 Bounds
Assume we observe n i.i.d. copies of (Z,S,Y )
denoted by (Zi, Si, Yi) for i = 1, . . . , n. Also as-
sume that the doomed principal strata is nonempty,
Pr[SP0 = (1,1)] > 0, so that the principal effect in
(10) is well defined. Bounds for (10) are presented
below under two additional assumptions: indepen-
dent treatment assignment, that is,
Z ∐ {Y (z), S(z)} for z = 0,1(11)
and monotone treatment response with respect to
S, that is,
Pr[S(0)≥ S(1)] = 1.(12)
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Assumption (11) will hold in randomized vaccine tri-
als. Monotonicity (12) assumes that the vaccine does
no harm at the individual level, that is, there are no
individuals who would be infected if vaccinated but
uninfected if not vaccinated. Monotonicity is equiv-
alent to assuming the harmed principal stratum is
empty. Note no such monotonicity assumption is be-
ing made regarding Y . Under (11), assumption (12)
implies P (S = 1|Z = 1) ≤ P (S = 1|Z = 0), which is
testable using the observed data. For the pertus-
sis example, the proportion infected in the vaccine
group was less than in the unvaccinated group; thus,
assuming (11), the data do not provide evidence
against (12).
Assuming independent treatment assignment and
monotonicity, (10) is partially identifiable from the
observable data. The left term of (10) can be written
E[Y (1)|SP0 = (1,1)]
=E[Y (1)|S(1) = 1]
(13)
=E[Y (1)|S(1) = 1,Z = 1]
=E[Y |S = 1,Z = 1],
where the first equality holds under (12), the second
equality under (11), and the third by causal consis-
tency. On the other hand, the right term of (10) is
only partially identifiable. To see this, note
E[Y (0)|S(0) = 1]
=E[Y (0)|SP0 = (1,1)]Pr[S(1) = 1|S(0) = 1](14)
+E[Y (0)|SP0 = (1,0)]Pr[S(1) = 0|S(0) = 1].
In (14), only E[Y (0)|S(0) = 1] and Pr[S(1) = s|
S(0) = 1] for s = 0,1 are identifiable. In particu-
lar, E[Y (0)|S(0) = 1] =E[Y |S = 1,Z = 0] by similar
reasoning to (13), and
Pr[S(1) = 1|S(0) = 1]
=
Pr[S(1) = 1]
Pr[S(0) = 1]
=
Pr[S = 1|Z = 1]
Pr[S = 1|Z = 0] ,
where the first equality holds under (12) and the
second under independent treatment assignment
(and causal consistency). The other two terms in
(14), namely E[Y (0)|SP0 = (1,1)] and E[Y (0)|SP0 =
(1,0)], are only partially identifiable. In words, in-
fected controls are a mixture of individuals in the
protected and doomed principal stratum and with-
out further assumptions the observed data do not
identify exactly which infected controls are doomed.
Therefore, the probability of severe disease when not
vaccinated in the doomed principal stratum is not
identified. Under (12), the data do however indicate
what proportion of infected controls are doomed
and this information provides partial identification
of E[Y (0)|SP0 = (1,1)], and hence (10).
For fixed values of E[Y (0)|S(0) = 1] and Pr[S(1) =
1|S(0) = 1], any pair of expectations (E[Y (0)|SP0 =
(1,1)],E[Y (0)|SP0 = (1,0)]) ∈ [0,1]2 satisfying (14)
will give rise to the same observed data distribution.
Equation (14) describes a line segment with nonpos-
itive slope intersecting the unit square as illustrated
in Figure 1. An upper bound of E[Y (0)|SP0 = (1,1)]
and thus a lower bound for (10) is achieved when the
line intersects the right or lower side of the square,
that is, when either
E[Y (0)|SP0 = (1,1)] = 1 or
(15)
E[Y (0)|SP0 = (1,0)] = 0.
Together (14) and (15) imply E[Y (0)|SP0 = (1,1)]
is bounded above by
min
{
1,
E[Y (0)|S(0) = 1]
Pr[S(1) = 1|S(0) = 1]
}
.(16)
Similarly, E[Y (0)|SP0 = (1,1)] is bounded below by
max
{
0,
(17)
E[Y (0)|S(0) = 1]−Pr[S(1) = 0|S(0) = 1]
Pr[S(1) = 1|S(0) = 1]
}
.
Combining (17) with (13) yields the upper bound on
the principal effect of interest (10) and combining
(16) with (13) yields the lower bound. These bounds
were derived by Rotnitzky and Jemiai (2003), Zhang
and Rubin (2003) and Hudgens, Hoering and Self
(2003). Consistent estimates of (16) and (17) can
be computed by replacing E[Y (0)|S(0) = 1] with∑
i YiI(Si = 1,Zi = 0)/
∑
i I(Si = 1,Zi = 0) and
Pr[S(1) = 1|S(0) = 1] with
min
{
1,
∑
i I(Si =Zi = 1)/
∑
i I(Zi = 1)∑
i I(Si = 1,Zi = 0)/
∑
i I(Zi = 0)
}
.
Returning to the pertussis vaccine study, the esti-
mated lower and upper bounds of (10) are −0.57 and
−0.15. These estimated bounds exclude zero, lead-
ing to the conclusion (ignoring sampling variability)
that vaccination lowers the risk of severe pertussis
in individuals who will become infected regardless
of whether they are vaccinated.
Note if Pr[S(1) = 1|S(0) = 1] = 1, that is, the
vaccine has no protective effect against infection,
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then the protected principal stratum SP0 = (1,0) is
empty and both (16) and (17) equal E[Y (0)|S(0) =
1] meaning that (10) is identifiable and equals
E[Y |Z = 1, S = 1] − E[Y |Z = 0, S = 1]. Intuitively,
the lack of vaccine effect against infection eliminates
the potential for selection bias.
As discussed in Section 2.5, incorporation of co-
variates can tighten bounds. For covariates X with
finite support, one simple approach of adjusting
for covariates entails determining bounds within
strata defined by the levels of X and then taking
a weighted average of the within strata bounds over
the distribution of X . For the bounds in (16) and
(17), adjustment for covariates will always lead to
bounds that are at least as tight as bounds unad-
justed for covariates (Lee (2009); Long and Hudgens
(2013)).
If the observed data provide evidence contrary
to monotonicity (12), then bounds may be ob-
tained under only (11). Without monotonicity (12),
the proportion of infected controls that are in the
doomed principal stratum is no longer identified but
may be bounded in order to arrive at bounds for
E[Y (0)|SP0 = (1,1)]. In addition, the harmed prin-
cipal stratum defined by SP0 = (0,1) is no longer
empty and thus E[Y (1)|SP0 = (1,1)] is no longer
identifiable from the observed data and may also be
bounded in a similar fashion to E[Y (0)|SP0 = (1,1)].
Details regarding these bounds without the mono-
tonicity assumption may be found in Zhang and Ru-
bin (2003) and Grilli and Mealli (2008).
3.4 Sensitivity Analysis
The bounds (16) and (17) are useful in bound-
ing the vaccine effect on Y in the doomed stratum.
However, these bounds may be rather extreme. An
alternative approach is to make an untestable as-
sumption that identifies the post-infection vaccine
effect on Y and then consider how sensitive the re-
sulting inference is to departures from this assump-
tion. For instance, assuming
Pr[Y (0) = 1|SP0 = (1,1)]
(18)
= Pr[Y (0) = 1|SP0 = (1,0)],
identifies (10). Hudgens and Halloran (2006) refer
to this as the no selection model. To examine how
inference varies according to departures from (18),
following Scharfstein, Rotnitzky and Robins (1999),
and Robins, Rotnitzky and Scharfstein (2000), con-
sider the following sensitivity parameter:
exp(γ) = (Pr[Y (0) = 1|SP0 = (1,1)]
/Pr[Y (0) = 0|SP0 = (1,1)])
(19)
· (Pr[Y (0) = 1|SP0 = (1,0)]
/Pr[Y (0) = 0|SP0 = (1,0)])−1.
In words, exp(γ) compares the odds of severe dis-
ease when not vaccinated in the doomed versus the
protected principal stratum. Assuming (18) corre-
sponds to γ = 0. A sensitivity analysis entails ex-
amining how inference about (10) varies as γ be-
comes farther from 0. For any fixed value of γ,
(10) is identified (see Figure 1) and can be consis-
tently estimated by maximum likelihood estimation
without any additional assumptions (Gilbert, Bosch
and Hudgens (2003)). The lower and upper bounds
(17) and (16) are obtained by letting γ →∞ and
γ→−∞. To see this, note that as γ→∞ (19) im-
plies in the limit that either
Pr[Y (0) = 1|SP0 = (1,1)] = 1 or
Pr[Y (0) = 1|SP0 = (1,0)] = 0,
which is equivalent to (15). Sensitivity analysis can
be conducted by letting γ range over a set of val-
ues Γ.
Tighter bounds can be achieved by placing restric-
tions on Γ, perhaps based on prior beliefs about γ
elicited from subject matter experts. For example,
Shepherd, Gilbert and Mehrotra (2007) surveyed 10
recognized HIV experts in order to elicit a plausible
range for a sensitivity parameter representing a de-
parture from the assumption of no selection bias be-
tween vaccinated and unvaccinated individuals who
acquired HIV during an HIV vaccine trial. Included
in this survey was the analysis approach, a brief ex-
planation of the potential for selection bias, the def-
inition of the sensitivity parameter being employed,
examples of the implications of certain sensitivity
parameter values on selection bias and possible jus-
tification for believing certain values of the sensitiv-
ity parameter. The expert responses to the survey
were fairly consistent and several written justifica-
tions for the respondents’ chosen ranges indicated
a high level of understanding of both the counter-
factual nature of the sensitivity parameter and the
need to account for selection bias.
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4. RANDOMIZED STUDIES WITH PARTIAL
COMPLIANCE
4.1 Global Average Treatment Effect
In a placebo controlled randomized trial where (5)
holds but there is non-compliance (i.e., individuals
are randomly assigned to treatment or control but
they do not necessarily adhere or comply with their
assigned treatment), the naive estimator is a con-
sistent estimator of the average effect of treatment
assignment. However, in this case parameters other
than the effect of treatment assignment may be of
interest. As in the last section, a principal effect
may be defined using compliance as the intermedi-
ate post-randomization variable over which to define
principal strata; namely the principal strata would
consist of individuals who would comply with their
randomization assignment if assigned treatment or
control or “compliers,” individuals who would al-
ways take treatment regardless of randomization or
“always takers,” individuals who never take treat-
ment “never takers” and individuals who take treat-
ment only if assigned control or “defiers.” A princi-
pal effect of interest might be the effect of treatment
in the complier principal stratum (Imbens and An-
grist (1994); Angrist, Imbens and Rubin (1996)), in
which case bounds and sensitivity analyses similar
to those in Section 3 are applicable. However, as
several authors including Robins (1989) and Robins
and Greenland (1996) have pointed out, such prin-
cipal effects may not be of ultimate public health in-
terest because they only apply to the subpopulation
of compliers in clinical trials, which may differ from
the population that elect to take treatment once li-
censed. For example, once efficacy is proved, a larger
subpopulation of people may be willing to take the
treatment. Effects defined on the subpopulation of
compliers are also of limited decision-making utility
because individual principal stratum membership is
generally unknown prior to treatment assignment
(Joffe (2011)).
Robins and Greenland (1996) suggested that in
settings where the trial population could be per-
suaded to take the treatment once licensed, a more
relevant public health estimand is the global aver-
age treatment effect, defined as the average effect of
actually taking treatment versus not taking treat-
ment given treatment assignment z. This causal es-
timand is similar to the average treatment effect
defined in Section 2, but requires generalizing the
potential outcome definitions used previously to in-
clude separate potential outcomes for each of the
four combinations of treatment assignment and ac-
tual treatment received. For further discussion re-
garding causal models in presence of noncompliance,
see Chickering and Pearl (1996) and Dawid (2003)
among others.
Suppose we observe data from a clinical trial
where each individual is randomly assigned to treat-
ment or control. Let Z indicate treatment assign-
ment where Z = 1 denotes treatment and Z = 0 de-
notes control. Suppose individuals do not necessarily
comply with their randomization assignment and let
S be a variable indicating whether or not treatment
was actually taken, where S = 1 denotes treatment
was taken and S = 0 otherwise. Thus, an individual
is compliant with their randomization assignment
if S = Z. Let Y be a binary outcome of interest.
Denote the potential treatment taken by S(z) for
z = 0,1, where S(z) = 1 indicates taking treatment
when assigned z and S(z) = 0 denotes not taking
treatment when assigned z. Let Y (z, s) denote the
potential outcome if an individual is assigned treat-
ment z but actually takes treatment s. Conceiving
of these potential outcomes depends on a suppo-
sition that trial participants who did not comply
in the trial could be persuaded to take the treat-
ment under other circumstances. Given this suppo-
sition, the global average treatment effect for each
treatment assignment z = 1 and z = 0 is defined as
GATEz =E[Y (z,1)−Y (z,0)]. For instance, GATE1
is the difference in the average outcomes under the
counterfactual scenario everyone was assigned vac-
cine and did comply versus the counterfactual sce-
nario everyone was assigned vaccine but did not
comply.
Bounds for GATEz are given below under three
assumptions: independent treatment assignment
Z ∐ {S(0), S(1), Y (0,0),
(20)
Y (0,1), Y (1,0), Y (1,1)};
monotonicity with respect to S
Pr[S(1)≥ S(0)] = 1;(21)
and the exclusion restriction
Y (0, s) = Y (1, s) for s= 0,1.(22)
Assumption (22) indicates treatment assignment
has no effect when the actual treatment taken is
held fixed. Under (22), GATE0 =GATE1 which we
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denote by GATE. In this case each individual has
two potential outcomes according to s= 0 and s= 1
[which could be denoted by Y (s) = Y (0, s) = Y (1, s)
for s = 0,1] and GATE is equivalent to the ATE
discussed in Section 2 with z replaced by s. Robins
(1989) derived bounds for GATE under several dif-
ferent combinations of (20)–(22) as well as some ad-
ditional assumptions such as monotonicity with re-
spect to S, that is, Y (z,1) ≥ Y (z,0) for z = 0,1.
Manski (1990) independently derived related re-
sults. Under (20)–(22), the sharp lower and upper
bounds on GATE are
−1+max
z
{Pr[Y = 1, S = 1|Z = z]}
(23)
+max
z
{Pr[Y = 0, S = 0|Z = z]}
and
1−max
z
{Pr[Y = 0, S = 1|Z = z]}
(24)
−max
z
{Pr[Y = 1, S = 0|Z = z]}.
Balke and Pearl (1997) derived sharp bounds for
GATE under a variety of assumptions, including
(20)–(22), by recognizing that the derivation of the
bounds is equivalent to a linear programming op-
timization problem. To see that bounds can be for-
mulated as a linear programming optimization prob-
lem, first note that GATE can be expressed as a lin-
ear combination of probabilities of the joint distri-
bution of L= (Y (0,0), Y (0,1), Y (1,0), Y (1,1), S(0),
S(1)) ∑
l1∈L1
Pr[L= l1]−
∑
l0∈L0
Pr[L= l0],(25)
where Ls is the set of possible realizations of L where
Y (0, s) = Y (1, s) = 1 for s= 0,1. Under independent
treatment assignment, there exists a linear transfor-
mation between the probabilities in the joint distri-
bution of L and the probabilities in the conditional
distribution of the observable random variables Y
and S given Z, namely
Pr[Y = y,S = s|Z = z] =
∑
l∈Oys·z
Pr[L= l],(26)
where Oys·z is the set of possible realizations of L
where S(z) = s and Y (z, s) = y for z, y, s= 0,1. To
find the sharp bounds, the objective function (25)
is minimized (or maximized) subject to the con-
straints (26), Pr[L = l] ≥ 0 for every l ∈ L, and
∑
l∈LPr[L = l] = 1 where L is the set of all possi-
ble realizations of L assuming (21) and (22). Opti-
mization may be accomplished using the simplex al-
gorithm and the dimension of this problem permits
obtaining a closed form solution involving probabil-
ities of the observed data distribution (Balke and
Pearl (1993)), namely (23) and (24).
If in addition to assumptions (20) and (22), it is
assumed that
E[Y (z,1)− Y (z,0)|Z = 1, S = s]
(27)
=E[Y (z,1)− Y (z,0)|Z = 0, S = s]
for s, z = 0,1 then GATE is identified and equals
E[Y |Z = 1]−E[Y |Z = 0]
E[S|Z = 1]−E[S|Z = 0](28)
(Herna´n and Robins (2006)). For s= 0 assumption
(27) is known as a no current treatment interaction
assumption (Robins (1994)), and expression (28) is
known as the instrumental variables estimand (Im-
bens and Angrist (1994); Angrist, Imbens and Ru-
bin (1996)). Sensitivity analyses may be conducted
by defining sensitivity parameters representing de-
partures from (20), (22) or (27) and then examin-
ing how inference about GATE varies as values of
these parameters change. For instance, Robins, Rot-
nitzky and Scharfstein (2000) define current treat-
ment interaction functions which represent a depar-
ture from (27) for s= 0.
4.2 Cholestyramine Example
To illustrate the GATE, we consider data pre-
sented in Pearl (2009, Section 8.2.6) on 337 sub-
jects who participated in a randomized trial to as-
sess the effect of cholestyramine on cholesterol re-
duction. Let Z = 1 denote assignment to cholestyra-
mine and Z = 0 assignment to placebo. Let S = 1
if cholestyramine was actually taken by the partic-
ipant and S = 0 otherwise. Let Y = 1 if the par-
ticipant had a response and Y = 0 otherwise, where
response is defined as reduction in the level of choles-
terol by 28 units or more. Pearl reported the follow-
ing observed proportions:
Pˆr[Y = 0, S = 0|Z = 0] = 0.919,
Pˆr[Y = 0, S = 0|Z = 1] = 0.315,
Pˆr[Y = 0, S = 1|Z = 0] = 0.000,
Pˆr[Y = 0, S = 1|Z = 1] = 0.139,
Pˆr[Y = 1, S = 0|Z = 0] = 0.081,
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Pˆr[Y = 1, S = 0|Z = 1] = 0.073,
Pˆr[Y = 1, S = 1|Z = 0] = 0.000,
Pˆr[Y = 1, S = 1|Z = 1] = 0.473.
No participants assigned placebo actually took
cholestyramine, suggesting the monotonicity as-
sumption (21) is reasonable. On the other hand,
38.8% of individuals assigned treatment did not ac-
tually take cholestyramine.
From (23) and (24), the bounds on GATE as-
suming (21), (20) and (22) are estimated to be
−1+max{0.000,0.473}+max{0.919,0.315} = 0.392
and 1−max{0,0.139} −max{0.081,0.073} = 0.780.
The positive sign of the estimated bounds indicates
the treatment is beneficial. Pearl interprets the es-
timated bounds as follows: “although 38.8% of the
subjects deviated from their treatment protocol, the
experimenter can categorically state that, when ap-
plied uniformly to the population, the treatment is
guaranteed to increase by at least 39.2% the proba-
bility of reducing the level of cholesterol by 28 points
or more.” Such an interpretation does not account
for sampling variability, the topic of Section 7.
5. MEDIATION ANALYSIS
5.1 Natural Direct and Indirect Effects
As demonstrated in Sections 3 and 4, independent
treatment assignment does not guarantee that the
causal estimand of interest will be identifiable. An-
other setting where this occurs is in mediation anal-
ysis, where researchers are interested in whether or
not the effect of a treatment is mediated by some
intermediate variable. Even in studies where treat-
ment is assigned randomly and there is perfect com-
pliance, confounding may exist between the interme-
diate variable and the outcome of interest such that
effects describing the mediated relationships will not
in general be identifiable. Thus, bounds and sensi-
tivity analysis may be helpful in drawing inference.
To illustrate, let Y be an observed binary out-
come of interest, and S a binary intermediate vari-
able observed some time between treatment assign-
ment Z and the observation of Y . The goal is to
assess whether and to what extent the effect of Z
on Y is mediated by or through S. Denote the po-
tential outcome of the intermediate variable under
treatment z by S(z) for z = 0,1 such that S = S(Z),
and the potential outcomes under treatment z and
intermediate s as Y (z, s) such that Y = Y (Z,S(Z)).
Here, as in the previous section, it is assumed that
both Z and S can be set to particular fixed val-
ues, such that there are four potential outcomes for
Y per individual. Unless otherwise specified, inde-
pendent treatment assignment (20) will be assumed
throughout this section.
Define the total effect of treatment to be E[Y (1,
S(1))− Y (0, S(0))], which is equivalent to the ATE
defined in Section 2.1. The total effect of treatment
can be decomposed in the following way:
E[Y (1, S(1))− Y (0, S(0))]
=E[Y (1, S(z))− Y (0, S(z))](29)
+E[Y (z′, S(1))− Y (z′, S(0)]
for z = 0,1 and z′ = 1 − z. The right-hand side of
(29) decomposes the total effect into the sum of
two separate effects. The first expectation on the
right-hand side of (29) is the natural direct effect
for treatment z, NDEz =E[Y (1, S(z))−Y (0, S(z))]
(Robins and Greenland (1992); Pearl (2001); Robins
(2003); Kaufman, Kaufman and MacLehose (2009);
Robins and Richardson (2010)). The natural di-
rect effect is the average effect of the treatment
on the outcome when the intermediate variable is
set to the potential value that would occur under
treatment assignment z. The second expectation
on the right-hand side of (29) is the natural indi-
rect effect, NIEz =E[Y (z,S(1))−Y (z,S(0))] (Pearl
(2001); Robins (2003); Imai, Keele and Yamamoto
(2010)). The natural indirect effect is the difference
in the average outcomes when treatment is set to z
and the intermediate variable is set to the value that
would have occurred under treatment compared to if
the intermediate variable were set to the value that
would have occurred under control.
Though the total effect is identifiable assuming
(20), the natural direct and indirect effects are not
identifiable since they entail E[Y (z,S(1−z))] which
depends on unobserved counterfactual distributions.
Sjo¨lander (2009) derived bounds for the natural di-
rect effects assuming only independent treatment
assignment (20) using the linear programming tech-
nique of Balke and Pearl (1997). This results in the
following sharp lower and upper bounds for NDE0
and NDE1:
max


−p11·0 − p10·0,
p11·1 + p01·0 − 1− p10·0,
p10·1 + p00·0 − 1− p11·0


(30)
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≤NDE0 ≤min


p01·0 + p00·0,
1− p00·1 + p01·0 − p10·0,
1− p01·1 + p00·0 − p11·0

 ,
max


−p01·1 − p00·1,
p00·0 − 1− p01·1 + p10·1,
p01·0 − 1− p00·1 + p11·1


(31)
≤NDE1 ≤min


p11·1 + p10·1,
1− p01·1 + p10·1 − p11·0,
1− p00·1 + p11·1 − p10·0

 ,
where pys·z =Pr(Y = y,S = s|Z = z). These bounds
may exclude 0, indicating a natural direct effect of
treatment z when the intermediate variable is set to
S(z) (ignoring sampling variability). There are in-
stances where the bounds in (30) and (31) may col-
lapse to a single point, for example, if p10·0 = p10·1 =
1. Using (29), bounds for NIE0 and NIE1 can be
obtained by subtracting the bounds for NDE1 and
NDE0 from the total effect, which is identified under
(20) and equal to (p11·1 + p10·1)− (p10·0 − p11·0).
Just as in Sections 2–4, monotonicity assumptions
can be made to tighten the above bounds. For in-
stance, if
Pr[S(0)≤ S(1)] = 1,
Pr[Y (0, s)≤ Y (1, s)] = 1 for s= 0,1 and
Pr[Y (z,0)≤ Y (z,1)] = 1 for z = 0,1,
are assumed, then Pr[L = l] = 0 for all l such that
(i) S(0) = 1 and S(1) = 0, (ii) Y (0, s) = 1 and
Y (1, s) = 0 for s = 0 or 1 or (iii) Y (z,0) = 1 and
Y (z,1) = 0 for s= 0 or 1, which restricts the feasi-
ble region of the linear programming problem. The
resulting sharp bounds for the natural direct effect
are
max
{
0, p01·0 − p01·1, p10·1 − p10·0,
p01·0 − p01·1 + p10·1 − p10·0
}
(32)
≤NDEz ≤ p10·1 + p11·1 − p10·0 − p11·0
(Sjo¨lander (2009)). The bounds (32) are always at
least as narrow as (30) and (31). Interestingly these
narrower bounds do not depend on z. The bounds in
(32) may also collapse to a single point, for example,
if p10·0 = p10·1 and p01·0 − p01·1 = p11·1 − p11·0.
The natural direct effect provides insight into
whether or not treatment yields additional bene-
fit on the outcome of interest when the influence
of treatment on the intermediate variable is elimi-
nated. However, researchers might also be interested
in what benefit is provided by treatment if the ef-
fect of the intermediate variable on the outcome is
eliminated or held constant. This question suggests
a different causal estimand known as the controlled
direct effect. Bounds for the controlled direct ef-
fect can be found in Pearl (2001), Cai et al. (2008),
Sjo¨lander (2009) and VanderWeele (2011a).
5.2 Sensitivity Analysis
As in other settings where the effect of interest
is not identifiable, sensitivity analysis in the media-
tion setting may be conducted by making untestable
assumptions that identify the direct or indirect ef-
fects. Then sensitivity of inference to departures
from these assumptions can be examined. For exam-
ple, if (20) holds, then the natural direct and indirect
effects are identified under the following additional
assumptions
Y (z, s)∐ S|Z for z, s= 0,1 and(33)
Y (z, s)∐ S(z′) for z, z′, s= 0,1(34)
(Pearl (2001); VanderWeele (2010)). Assumption
(33) would be valid if subjects were randomly as-
signed S within different levels of treatment assign-
ment Z. In settings where S is not randomly as-
signed, (33) might be considered plausible if it is
believed that conditional on Z there are no variables
which confound the mediator–outcome relationship.
Both assumptions (33) and (34) will not hold in gen-
eral if Z has an effect on some other intermediate
variable, say R, which in turn has an effect on both
S and Y . Thus, (33) and (34) may fail unless the
mediator S occurs shortly after treatment Z. Under
assumptions (20), (33) and (34),
NDEz = (−1)z
∑
s
{E[Y |Z = 1− z,S = s]
−E[Y |Z = z,S = s]}Pr[S = s|Z = z]
and
NIEz = (−1)z
∑
s
E[Y |Z = z,S = s]
· {Pr[S = s|Z = 1− z]
−Pr[S = s|Z = z]}.
Because assumptions (33) and (34) cannot be em-
pirically tested, sensitivity analysis should be con-
ducted. Similar to Section 2.4, sensitivity analysis
might proceed by positing the existence of an un-
measured confounding variable U associated with
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the potential mediator values S(z) and the poten-
tial outcomes Y (z, s) for z, s= 0,1. Assumption (33)
would then replaced by Y (z, s)∐ S|{Z,U} and (34)
by Y (z, s) ∐ S(z′)|U for s, z, z′ = 0,1. Sensitivity
analysis would then proceed by exploring how in-
ference about the natural direct and indirect effects
changes as the magnitude of the associations of U
with S(z) and Y (s, z′) for z, z′, s= 0,1 vary. For fur-
ther details regarding bounds and sensitivity anal-
ysis in mediation analysis, see Imai, Keele and Ya-
mamoto (2010), VanderWeele (2010) and Hafeman
(2011).
6. LONGITUDINAL TREATMENT
6.1 Background
In Sections 2–5, treatment is assumed to remain
fixed across follow up time and outcomes are one-
dimensional. However, frequently researchers are in-
terested in assessing causal effects comparing longi-
tudinal outcomes for patients on different treatment
regimens where treatment may vary in time. As the
number of times at which an individual may receive
treatment increases, the number of possible treat-
ment regimens increases exponentially. Because each
treatment regimen corresponds to a separate poten-
tial (longitudinal) outcome and only one potential
outcome is ever observed, the fraction of potential
outcomes that are unobserved quickly grows close to
one as the number of possible treatment times in-
creases. As in other settings, unless treatment reg-
imens are randomly assigned, regimen effects will
not be identifiable without additional assumptions.
In the longitudinal setting, bounds will typically be
largely uninformative because of the high propor-
tion of unobserved potential outcomes. Therefore,
analyses usually proceed by invoking modeling as-
sumptions that render treatment effects identifiable
and then conducting sensitivity analysis correspond-
ing to key untestable modeling assumptions.
Models for potential outcomes as functions of
covariates (such as treatment) and possibly other
potential outcomes are often referred to as struc-
tural models. For longitudinal potential outcomes
and treatments, popular models include struc-
tural nested models and marginal structural models
(Robins, Rotnitzky and Scharfstein (2000); Robins
(1999); van der Laan and Robins (2003); Brumback
et al. (2004)). In Section 6.2 below, we consider a
marginal structural model where the treatment ef-
fect is identified assuming conditionally independent
treatment assignment. Sensitivity analyses explor-
ing departures from this assumption are then con-
sidered in Section 6.3.
6.2 Marginal Structural Model
Consider a study where individuals possibly re-
ceive treatment at τ fixed time points (i.e., study
visits). In general let A¯(t) = (A(0), . . . ,A(t)) rep-
resent the history of variable A up to time t and
A¯ be the entire history of variable A such that
A¯ = A¯(τ). Let z(t) = 1 indicate treatment at visit
t, and z(t) = 0 otherwise such that z¯ represents a
treatment regimen for visits 0, . . . , τ . Denote the ob-
served treatment regimen up to time t as Z¯(t). Let
Y be some outcome of interest that may be cate-
gorical or continuous, and denote the potential out-
come of Y at visit t for regimen z¯ by Y (z¯, t) and
the observed outcome by Y (t). Let X¯(t) denote the
history of some set of time varying covariates up to
time t, where X(0) denotes the baseline covariates.
Assume for simplicity there is no loss to follow-up or
noncompliance such that we observe n i.i.d. copies
of (Z¯, Y¯ , X¯).
Consider the following marginal structural model
of the mean potential outcome were the entire pop-
ulation to follow regimen z¯ up to time t:
g(E[Y (z¯, t)|X(0) = x(0)])
(35)
= β0 + β1 cum[z¯(t− 1)] + β2t+ β3x(0)
for t ∈ {1, . . . , τ}, where cum[z¯(t− 1)] =∑t−1k=1 z(k)
and g(·) is an appropriate link function. The causal
estimand of interest is β1, the regression coefficient
for cum[z¯(t − 1)], which is the effect of having re-
ceived treatment at one additional visit prior to time
t conditional on baseline covariates X(0). Because
(35) involves counterfactual outcome distributions,
β1 is not identifiable without additional assump-
tions. One additional assumption is conditionally in-
dependent treatment assignment
Y (z¯, t)∐Z(k)|{Z¯(k− 1), X¯(k)}
(36)
for all z¯ and t > k
(Robins, Rotnitzky and Scharfstein (2000); Robins
(1999); Brumback et al. (2004)). This assumption
is true if the potential outcome at visit t under
treatment regimen z¯ is independent of the observed
treatment at visit k given the history of treatment
up to visit k − 1 and the covariate history up to
visit k. Assuming both a correctly specified model
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(35) and conditionally independent treatment as-
signment (36), fitting the following model to the ob-
served data:
g(E[Y (t)|Z¯(t− 1) = z¯(t− 1),X(0) = x(0)])
= η0 + η1 cum[z¯(t− 1)] + η2t+ η3x(0),
using generalized estimating equations with an inde-
pendent working correlation matrix and time vary-
ing inverse probability of treatment weights (IPTW)
yields an estimator ηˆ1 that is consistent for β1
(Tchetgen Tchetgen et al., 2012a, 2012b).
6.3 Sensitivity Analysis
If assumption (36) does not hold, then the IPTW
estimator ηˆ1 is not necessarily consistent. Because
(36) is not testable from the observed data, sensi-
tivity analysis might be considered to assess robust-
ness of inference to departures from (36). Following
Robins (1999) and Brumback et al. (2004), let
c(t, k, z¯(t− 1), x¯(k))
=E[Y (z¯, t)|Z¯(k) = z¯(k), X¯(k) = x¯(k)]
−E[Y (z¯, t)|Z(k) = 1− z(k),
Z¯(k− 1) = z¯(k− 1), X¯(k) = x¯(k)]
for t > k and z¯ such that Pr[Z(k) = z(k)|Z¯(k− 1) =
z¯(k − 1)] is bounded away from 0 and 1. The func-
tion c quantifies departures from the conditional in-
dependent treatment assignment assumption (36)
at each visit t > k, where c(t, k, z¯(t − 1), x¯(k)) = 0
for all z¯ and t > k if (36) holds. For the identity
link, a bias adjusted estimator of the causal effect
β1 may be obtained by recalculating the IPTW esti-
mator with the observed outcome Y (t) replaced by
Y γ(t) = Y (t)− b(Z¯(t− 1), X¯(t− 1)) where
b(Z¯(t− 1), X¯(t− 1))
=
t−1∑
k=0
c(t, k, Z¯(t− 1), X¯(k))
· f [1−Z(k)|Z¯(k− 1), X¯(k)]
and f [z(k)|z¯(k − 1), x¯(k)] = Pˆr[Z(k) = z(k)|Z¯(k −
1) = z¯(k−1), X¯(k) = x¯(k)] is an estimate of the con-
ditional probability of the observed treatment based
on some fitted parametric model (Brumback et al.
(2004)). Provided this parametric model and c are
both correctly specified, this bias adjusted estima-
tor, say η˜1, is consistent for β1. Sensitivity analysis
proceeds by examining how η˜1 changes when vary-
ing sensitivity parameters in c(t, k, z¯(t− 1), x¯(k)).
Because c(t, k, z¯(t − 1), x¯(k)) is not identifiable
from the observable data, Robins (1999) recom-
mends choosing a particular c that is easily explain-
able to subject matter experts to facilitate eliciting
plausible ranges of the sensitivity parameters. As an
example of a particular c, Brumback et al. (2004)
suggest c(t, k, z¯(t− 1), x¯(k)) = γ{2z(k)− 1} where γ
is an unidentifiable sensitivity analysis parameter.
Note that c(t, k, z¯(t− 1), x¯(k)) = γ for z(k) = 1 and
c(t, k, z¯(t− 1), x¯(k)) =−γ for z(k) = 0. Thus, γ > 0
(γ < 0) corresponds to subjects receiving treatment
at time k having greater (smaller) mean potential
outcomes at future visit t than those who did not re-
ceive treatment at visit k. When γ = 0, Y (t) = Y γ(t)
and therefore η˜1 = ηˆ1. The function c might depend
on the baseline covariates X(0) or the time-varying
covariates X¯(k). In this case, as in Section 2.5, care
should be taken in clearly communicating the sen-
sitivity parameters’ relationship to these covariates
when eliciting plausible ranges from subject mat-
ter experts. Another consideration when choosing a
function c is whether it will allow for the sharp null
of no treatment effect, that is, for all individuals
Y (z¯, t) = Y (z¯′, t) for all z¯, z¯′, t. The example func-
tion c presented above allows for the sharp null. See
Brumback et al. (2004) for other example c func-
tions and further discussion of sensitivity analysis
for marginal structural models.
7. IGNORANCE AND UNCERTAINTY
REGIONS
Treatment effect bounds describe ignorance due to
partial identifiability but do not account for uncer-
tainty due to sampling error. This section discusses
some methods to appropriately quantify uncertainty
due to sampling variability when drawing inference
about partially identifiable treatment effects. Over
the past decade, a growing body of research, es-
pecially in econometrics, has considered inference
of partially identifiable parameters. The approach
presented below draws largely upon Vansteelandt
et al. (2006), who considered methods for quantify-
ing uncertainty in the general setting where miss-
ing data causes partial identifiability. As questions
about treatment (or causal) effects can be viewed
as missing data problems, the approach of Vanstee-
landt et al. generally applies (under certain assump-
tions) to the type of problems considered through-
out this paper. This approach builds on earlier work
by Robins (1997) and others.
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7.1 Ignorance Regions
Let L be a vector containing the potential out-
comes for an individual, let O denote the ob-
served data vector, and let R be a vector con-
taining indicator variables denoting whether the
corresponding component of L is observed. For
example, L = (Y (1), Y (0)), O = (Z,Y ), and R =
(Z, (1− Z)) for the scenario described in Section 2
and L = (Y (1), Y (0), S(1), S(0)), O = (Z,Y,S) and
R = (Z, (1 − Z),Z, (1 − Z)) for the scenario de-
scribed in Section 3. Denote the distribution of
(L,R) by f(L,R) and let f(L) =
∫
f(L,R)dR. The
goal is to draw inference about a parameter vector
β which is a functional of the distribution of poten-
tial outcomes L; this is sometimes made explicit by
writing β = β{f(L)}. Denote the true distribution
of (L,R) by f0(L,R) and the true value of β by
β0 = β{f0(L)}. For example, β0 = E[Y (1) − Y (0)]
for the scenario described in Section 2 and β0 =
E[Y (1) − Y (0)|SP0 = (1,1)] for the scenario de-
scribed in Section 3. Denote the true observed data
distribution by f0(O) =
∫
f0(L,R)dL(1−R) where
L(1−r) denotes the missing part of L when R = r
(i.e., the unobserved potential outcomes). The chal-
lenge in drawing inference about β0 is that there
may be multiple full data distributions f(L,R) that
marginalize to the true observed data distribution,
that is, f0(O) =
∫
f(L,R)dL(1−R) for some f 6= f0.
When this occurs, β may be only partially identifi-
able from O, in which case bounds can be derived
for β0 as illustrated in the sections above.
The set of values of β{f(L)} such that f(L,R)
marginalizes to the true observed data distribu-
tion is sometimes called the ignorance region or
the identified set. These ignorance regions or in-
tervals are distinct from traditional confidence in-
tervals in that as the sample size tends to in-
finity these intervals will not shrink to a single
point when β is partially identifiable. The igno-
rance region for β can be defined formally as fol-
lows. Following Robins (1997), define a class M(γ)
of full data laws indexed by some sensitivity pa-
rameter vector γ to be nonparametrically identi-
fied if for each observed data law f(O) there exists
a unique law f(L,R;γ) ∈M(γ) such that f(O) =∫
f(L,R;γ)dL(1−R). In other words, the classM(γ)
contains a unique distribution that marginalizes to
each possible observed data distribution. For ex-
ample, for the sensitivity analysis approach in Sec-
tion 3.4, Hudgens and Halloran (2006, §4.3.3) de-
fined a class of full data laws indexed by γ given
in (19) that is nonparametrically identified. The ig-
norance region for β is formally defined to be
irf0(β,Γ)
=
{
β{f(L)} : f(L)
=
∫
f(L,R;γ)dR for some(37)
f(L,R) ∈M(Γ) such that∫
f(L,R;γ)dL(1−R) = f0(O)
}
,
where Γ is the set of all possible values of γ un-
der whatever set of assumptions is being invoked
and M(Γ) = ⋃γ∈ΓM(γ). Assume M(Γ) contains
the true full data distribution, that is, f0(L,R) =
f(L,R,γ0) for some γ0 ∈ Γ. [For considerations
when M(Γ) does not contain the true full data dis-
tribution, see Todem, Fine and Peng (2010).] Be-
causeM(γ) is nonparametrically identified, for each
γ ∈ Γ there is a single β(γ) = β{∫ f(L,R;γ)dR)} in
the ignorance region (37). If M(Γ) includes all pos-
sible full data distributions that marginalize to any
possible observed data distribution, then the igno-
rance region will contain the bounds.
In practice, the ignorance region will be unknown
because it depends on the unknown true observed
data distribution f0(O). For γ fixed, β(γ) is iden-
tifiable from the observed data and the ignorance
region can be estimated by estimating β(γ) for each
value of γ ∈ Γ, denoted by βˆ(γ). The resulting esti-
mator of irf0(β,Γ) is then {βˆ(γ) :γ ∈ Γ}. For scalar
β(γ), let βˆl = infγ∈Γ{βˆ(γ)} and βˆu = supγ∈Γ{βˆ(γ)}
such that the estimated ignorance region is con-
tained in the interval [βˆl, βˆu].
7.2 Uncertainty Regions
Estimated ignorance regions convey ignorance due
to partial identifiability and do not reflect sampling
variability in the estimates. Indeed much of the lit-
erature on bounds and sensitivity analysis of treat-
ment effects tends to report estimated ignorance re-
gions and either ignores sampling variability or em-
ploys ad-hoc inferential approaches such as point-
wise confidence intervals conditional on each value
of the unidentifiable sensitivity parameter. More re-
cent developments have provided a formal frame-
work for conducting inference in partial identifiabil-
ity settings (Imbens and Manski (2004); Vanstee-
landt et al. (2006); Romano and Shaikh (2008);
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Bugni (2010); Todem, Fine and Peng (2010)). The
main focus in this research has been the construc-
tion of confidence regions for either the parameter
β0 or the ignorance region irf0(β0,Γ).
Following Vansteelandt et al. (2006), a (1 − α)
pointwise uncertainty region for β0 is defined to be
a region URp(β,Γ) such that
inf
γ∈Γ
Prf0{β(γ) ∈URp(β,Γ)} ≥ 1− α,
where Prf0{·} denotes probability under f0(O).
That is, URp(β,Γ) contains β(γ) with at least prob-
ability 1− α for all γ ∈ Γ. In particular, assuming
γ0 ∈ Γ, then URp(β,Γ) will contain β0 = β(γ0) with
at least probability 1− α.
An appealing aspect of pointwise uncertainty re-
gions is that they retain the usual duality between
confidence intervals and hypothesis testing. Namely,
one can test the null hypothesis H0 :β0 = βc versus
Ha :β0 6= βc for some specific βc at the α significance
level by rejecting H0 when the (1−α) pointwise un-
certainty region URp(β,Γ) excludes βc. This is easily
shown by noting for βc = β(γ0)
Prf0 [reject H0]
= 1−Prf0{β(γ0) ∈URp(β,Γ)}
≤ 1− infγ∈ΓPrf0{β(γ) ∈URp(β,Γ)} ≤ α,
where the last inequality follows because URp(β,Γ)
is a (1− α) pointwise uncertainty region.
Various methods under different assumptions have
been proposed for constructing pointwise uncer-
tainty regions. Imbens and Manski (2004) and
Vansteelandt et al. (2006) proposed a simple method
for constructing pointwise uncertainty regions for a
scalar β with ignorance region [βl, βu]. Let γl, γu ∈ Γ
be the values of the sensitivity parameter such that
βl = β(γl) and βu = β(γu). Assume
There exist βˆl such that
√
n(βˆl − βl) d→N(0, σ2l )
(38)
and βˆu such that
√
n(βˆu − βu) d→N(0, σ2u).
The values γl and γu are the same(39)
for all possible observed data laws.
Under assumptions (38) and (39), an asymptotic
(1− α) pointwise uncertainty interval for β0 is
URp(β,Γ)
(40)
= [βˆl − cασ̂l/
√
n, βˆu + cασ̂u/
√
n],
where cα satisfies
Φ
(
cα +
√
n(βˆu − βˆl)
max{σ̂l, σ̂u}
)
−Φ(−cα) = 1−α,(41)
Φ(·) denotes the cumulative distribution function of
a standard normal variate, and σ̂l and σ̂u are con-
sistent estimators of σl and σu, respectively (Im-
bens and Manski (2004); Vansteelandt et al. (2006)).
Note if βˆu − βˆl > 0 and n is large such that the
left-hand side of (41) is approximately equal to
1−Φ(−cα), then cα ≈ z1−α, the (1−α) quantile of a
standard normal distribution. In contrast, if βˆu = βˆl,
then cα = z1−α/2.
In addition to the pointwise uncertainty region,
Horowitz and Manski (2000) and Vansteelandt et al.
(2006) define a (1−α) strong uncertainty region for
β0 to be a region URs(β,Γ) such that
Prf0{irf0(β,Γ)⊆URs(β,Γ)} ≥ 1−α,
that is, URs(β,Γ) contains the entire ignorance re-
gion with probability at least 1 − α. Whereas the
pointwise uncertainty region can be viewed as a
confidence region for the partially identifiable tar-
get parameter β0, the strong uncertainty region is a
confidence region for the ignorance region irf0(β,Γ).
Clearly, any strong uncertainty region will also be
a (conservative) pointwise uncertainty region as
β0 ∈ irf0(β,Γ). Under assumptions (38) and (39),
an asymptotic (1 − α) strong uncertainty interval
for scalar β0 is simply
URs(β,Γ)
(42)
= [βˆl − z1−α/2σ̂l/
√
n, βˆu + z1−α/2σ̂u/
√
n].
Note that (42) is equivalent to the union of all
pointwise (1− α) confidence intervals for β(γ) un-
derM(γ) over all γ ∈ Γ, which is a simple approach
often employed when reporting sensitivity analysis.
Because strong uncertainty intervals are necessarily
pointwise intervals, this simple approach is also a
valid method for computing pointwise intervals, al-
though intervals based on (40) will always be as or
more narrow.
The two key assumptions (38) and (39) may not
hold in general. For example, (38) may not hold
for all possible observed data distributions, partic-
ularly for extreme values of γl or γu. Assumption
(39) may not hold if different observed data dis-
tributions place different constraints on the possi-
ble range of γ or if Γ is chosen by the data ana-
lyst on the basis of the observed data. If (38) or
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(39) does not hold, alternative inferential methods
are needed (e.g., see Vansteelandt and Goetghe-
beur (2001); Horowitz and Manski (2006); Cher-
nozhukov, Hong and Tamer (2007); Romano and
Shaikh (2008); Stoye (2009); Todem, Fine and Peng
(2010); Bugni (2010)).
A third approach to quantifying uncertainty due
to sampling variability is to consider β(·) as function
of γ and construct a (1−α) simultaneous confidence
band for the function β(·). That is, a random func-
tion CB(·) is found such that
Prf0{β(γ) ∈CB(γ) for all γ ∈ Γ} ≥ 1−α.
It follows immediately that
⋃
γ∈ΓCB(γ) is a strong
uncertainty region (and thus a pointwise uncertainty
region as well). Todem, Fine and Peng (2010) sug-
gest a bootstrap approach to constructing confi-
dence bands.
Whether pointwise uncertainty regions, strong un-
certainty regions, or confidence bands are preferred
will be context specific. Typically, it is of inter-
est to draw inference about a single target pa-
rameter and not the entire ignorance region. Thus,
in general pointwise uncertainty regions may have
greater utility than strong uncertainty regions. Be-
cause strong uncertainty regions are necessarily con-
servative pointwise uncertainty regions, the strong
regions can be useful in settings where determining
a pointwise region is more difficult. Additionally, in
some settings it may be of interest to assess whether
β is nonzero, for example, if β denotes the effect of
treatment. In these settings, computing a confidence
band CB(·) has the advantage of providing the sub-
set of Γ where the null hypothesis β(γ) = 0 can be
rejected. This is especially appealing if γ is scalar,
in which case a confidence band (as in Figure 3 of
Todem, Fine and Peng (2010)) provides a simple ap-
proach to reporting sensitivity analysis results. On
the other hand, if γ is multidimensional, visualizing
confidence bands can be difficult and instead report-
ing the (pointwise or strong) uncertainty region may
be more practical.
7.3 Data Example
Returning to the pertussis vaccine study described
in Section 3, an analysis that ignores the potential
for selection bias might entail computing a naive
estimator (the difference in empirical means of Y
between the vaccinated and unvaccinated amongst
those infected) along with a 95% Wald confidence
interval, which would be −0.31 (95% CI −0.38,
Fig. 1. Graphical depiction of the bounds and sensitivity
analysis model described in Sections 3.3 and 3.4. The solid
thin line with negative slope represents a set of joint distribu-
tion functions of (Z,S(1), S(0), Y (1), Y (0)) that all give rise
to the same distribution of the observable random variables
(Z,S,Y ). The four dotted curves depict the log odds ratio se-
lection model for γ = 0,1,2,4. The γ = 0 model is equivalent to
the no selection model. Each selection model identifies exactly
one pair of expectations from this set, rendering the principal
effect (10) identifiable. The thick black lines on the edge of
the unit square correspond to the lower bound of the principal
effect.
−0.23). If the sensitivity analysis approach in Sec-
tion 3.4 is applied, the parameter of interest β(γ) =
E[Y (1)−Y (0)|SP0 = (1,1)] is identified for fixed val-
ues of the sensitivity analysis parameter γ given in
(19). For fixed γ, E[Y (0)|SP0 = (1,1)] is determined
by the intersection of the negative sloped line (14)
and the curve (19), which is illustrated in Figure 1
for the pertussis data. Because E[Y (0)|SP0 = (1,1)]
increases with γ, β(γ) is a monotonically decreas-
ing function of γ. Therefore γl and γu equal the
maximum and minimum values of Γ regardless of
the observed data law, indicating (39) holds pro-
vided that Γ is chosen by the analyst independent
of the observed data. For γ fixed and finite, β(γ)
can be estimated via nonparametric maximum like-
lihood (i.e., without any additional assumptions).
This estimator will be consistent and asymptoti-
cally normal under standard regularity conditions
if Pr[S(0) > S(1)] > 0 (i.e., the vaccine has a pro-
tective effect against infection). For γ = ±∞ and
Pr[S(0) > S(1)]> 0, Lee (2009) proved that the es-
timators of the bounds similar to those given in Sec-
tion 3.3 are consistent and asymptotically normal
for a continuous outcome Y . The limiting distribu-
tion of the estimator of the upper bound (γ =−∞)
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Table 1
Pertussis vaccine study data: Estimated ignorance regions
and 95% pointwise and strong uncertainty regions of
β =E[Y (1)− Y (0)|SP0 = (1,1)] for different Γ
Γ irf0(β,Γ) URp(β,Γ) URs(β,Γ)
[−3,3] [−0.49,−0.17] [−0.58,−0.07] [−0.59,−0.06]
[−5,5] [−0.55,−0.15] [−0.66,−0.05] [−0.69,−0.03]
[−10,10] [−0.57,−0.15] [−0.70,−0.04] [−0.73,−0.02]
(−∞,∞) [−0.57,−0.15] [−0.70,−0.04] [−0.73,−0.02]
for a binary outcome will be normal if in addition
1−E[Y |S = 1,Z = 0] 6= Pr[S = 1|Z = 1]
Pr[S = 1|Z = 0] ,(43)
and similarly the estimator of the lower bound (γ =
∞) will be asymptotically normal if in addition
E[Y |S = 1,Z = 0] 6= Pr[S = 1|Z = 1]
Pr[S = 1|Z = 0] .(44)
Likelihood ratio tests for the null hypotheses that
(43) and (44) do not hold yield p-values p < 10−4
and p = 0.18, respectively, indicating strong evi-
dence that (43) holds and equivocal evidence regard-
ing (44). Assuming (43) and (44) both hold implies
(38), such that (40) and (42) can be used to con-
struct (1− α) pointwise and strong uncertainty in-
tervals for β0. Estimated ignorance and uncertainty
intervals of β0 for different choices of Γ are given in
Table 1 and Figure 2, with standard error estimates
obtained using the observed information. Even for
Γ = (−∞,∞) both the pointwise and strong uncer-
tainty intervals exclude zero, indicating a significant
effect of vaccination. In particular, with 95% confi-
dence we can conclude the vaccine decreased the risk
of severe disease among individuals who would have
become infected regardless of vaccination.
8. DISCUSSION
This paper considers conducting inference about
the effect of a treatment (or exposure) on an out-
come of interest. Unless treatment is randomly as-
signed and there is perfect compliance, the effect of
treatment may be only partially identifiable from
the observable data. Through the five settings in
Sections 2–6, we discussed two approaches often em-
ployed to address partial identifiability: (i) bound-
ing the treatment effect under minimal assump-
tions, or (ii) invoking additional untestable assump-
tions that render the treatment effect identifiable
Fig. 2. Estimated ignorance regions irf0(β,Γ) and 95%
pointwise uncertainty regions URp(β,Γ) for the pertussis vac-
cine example in Section 7.3. The principal effect (10) is de-
noted β and Γ = [−γu, γu] for γu along the horizontal axis.
The curve given by the lower boundary of the area with black
slanted lines corresponds to βˆl, the minimum of the estimated
ignorance regions, and the upper bound of the area with black
slanted lines corresponds to βˆu, the maximum of the estimated
ignorance region. The curve given by the lower (upper) bound-
ary of the gray shaded area corresponds to the minimum (max-
imum) of the 95% pointwise uncertainty region.
and then conducting sensitivity analysis to assess
how inference about the treatment effect changes
as the untestable assumptions are varied. Incor-
porating uncertainty due to sampling variability
was discussed in Section 7, and throughout large-
sample frequentist methods were considered. Anal-
ogous Bayesian approaches to partial identification
(Gustafson (2010); Moon and Schorfheide (2012);
Richardson, Evans and Robins (2011)) and sensi-
tivity analysis (McCandless, Gustafson and Levy
(2007); Gustafson et al. (2010)) have also been de-
veloped.
Determining treatment effect bounds is essentially
a constrained optimization problem, where the con-
straints are determined by the relationship between
the distributions of the observable random variables
and of the potential outcomes under whichever as-
sumptions are being made. In simple cases, such
as in Section 2.1, bounds can easily be derived
from first principles and may have simple closed
forms; in more complicated settings, such as in Sec-
tion 4, bounds may be determined using linear pro-
gramming or other optimization methods. In many
cases, calculating bounds under minimal assump-
tions may seem to be a meaningless exercise because
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the bounds are often quite wide and may not ex-
clude the null of no treatment effect as seen with
the “no assumptions” bounds in Section 2. On the
contrary, in settings like this Robins and Greenland
(1996) write: “Some argue against reporting bounds
for nonidentifiable parameters, because bounds are
often so wide as to be useless for making public
health decisions. But we view the latter problem as
a reason for reporting bounds in conjunction with
other analyses: Wide bounds make clear that the de-
gree to which public health decisions are dependent
on merging the data with strong prior beliefs.”
Bounds may be narrowed by reducing the feasible
region of the optimization problem. This may be ac-
complished by considering further assumptions that
place restrictions on either the distributions of the
potential outcomes, the distributions of the observ-
able random variables, or both. Assumptions that
place restrictions on the observable random vari-
ables may have implications which are testable. If
the observed data provide evidence against any as-
sumptions being considered, bounds should be com-
puted without making these assumptions. Those as-
sumptions without testable implications can only be
determined to be plausible or not by subject matter
experts.
A potentially less conservative approach to com-
puting bounds is to make untestable assumptions
which identify the causal estimand and then assess
the robustness of inference drawn to departures from
these assumptions in a sensitivity analysis. A general
guideline for specifying the sensitivity analysis pa-
rameters representing these departures is to choose
parameters that are easily interpretable to subject
matter experts. Parameter specification will depend
on whether or not sensitivity analysis is conducted
by directly modeling the association of an unmea-
sured confounder U with treatment selection and
the potential outcomes. Sensitivity analyses based
on this approach are applicable when the existence
of U is known and there is some historical knowledge
of the magnitude association of U with Z and the
potential outcomes (Robins (1999); Brumback et al.
(2004)). Otherwise, alternative approaches based on
directly modeling the unobserved potential outcome
distributions may be preferred. A second guiding
principle should be to avoid specifications of sen-
sitivity parameters that place restrictions on the
distributions of observable random variables that
are not empirically supported. A third considera-
tion when conducting sensitivity analysis concerns
determining a plausible region of the sensitivity pa-
rameters. That the region be chosen prior to data
analysis is in general necessary for inference, such
as described in Section 7, to be valid. Choice of
the region of the sensitivity parameters may be dic-
tated by whether one wants to consider only mild or
also severe departures from the identifying assump-
tions. If the identifying assumption in question is
considered plausible, then it may be that only mild
departures from the assumption are deemed neces-
sary for the sensitivity analysis. In this case, sub-
ject matter experts can be consulted to determine,
prior to data analysis, a plausible region for the sen-
sitivity parameters. If, on the other hand, severe
departures from untestable identifying assumptions
are to be entertained, sensitivity analyses should be
conducted over all possible values of the sensitivity
parameters. Sensitivity analyses which consider all
possible full data distributions that marginalize to
the observed data distribution will yield ignorance
regions containing the bounds.
Though the examples presented here demonstrate
the broad scope of scenarios where bounds and sen-
sitivity analysis methods have been derived and
employed to draw inference about treatment ef-
fects, they certainly are not exhaustive of all set-
tings where these methods have been developed.
For instance, VanderWeele, Mukherjee and Chen
(2012) consider sensitivity analysis to unmeasured
confounding for causal interaction effects. Bounds
and sensitivity analysis methods have also recently
been considered in the presence of interference, that
is, in settings where treatment of one individual may
affect the outcome of another individual, such as
in social networks (Ver Steeg and Galstyan (2010);
VanderWeele (2011b); Manski (2013)). For stud-
ies where sensitivity analyses are planned or antic-
ipated, Rosenbaum and colleagues have examined
how aspects of study design and the choice of sta-
tistical tests or estimators may affect the power or
precision of the sensitivity analyses to be conducted
(Heller, Rosenbaum and Small (2009); Rosenbaum,
2010a; 2010b; 2011).
Bounds and sensitivity analyses of treatment ef-
fects have been utilized in various substantive set-
tings, such as biomedical research (e.g., Cole et al.
(2005); Rerks-Ngarm et al. (2009); VanderWeele and
Herna´ndez-Diaz (2011); Hu et al. (2012)) and eco-
nomics (e.g., Heckman (2001); Sianesi (2004); Arm-
strong, Guay and Weber (2010)). Nonetheless, de-
spite the wide range of settings in which these meth-
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ods are applicable, their use in substantive set-
tings remains somewhat limited in frequency. Given
the large amount of literature detailing their broad
scope of applicability and that formal inferential
methods for partially identifiable parameters are
now available, hopefully these approaches will be
employed with greater frequency in substantive set-
tings in the future.
The sensitivity analyses described throughout this
paper focus on departures from untestable assump-
tions which identify treatment effects. Other types
of sensitivity analyses might be considered as well,
for example, to assess how robust inferences are to
various analytical decisions that are invariably made
in data analysis. Rosenbaum (2002, Section 11.9)
refers to such assessment as “stability analysis,” in
contrast to the types of sensitivity analyses dis-
cussed above. See Rosenbaum (1999, 2002) and
Morgan and Winship (2007, Section 6.2) for fur-
ther discussion regarding various types of sensitivity
analyses beyond the type considered here.
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